Acetylon Grabs $27M in Venture Cash for Next-Gen HDAC Inhibitor

Boston-based Acetylon Pharmaceuticals has raised $27M to launch a Phase I/II study of their proprietary HDAC6 specific inhibitor, ACY-1215. This drug target is of particular interest in ALS because of data suggesting that HDAC6 regulates various proteins involved in axonal transport, including tubulin and possibly dynactin.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail